Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
Cybin announces the API synthesis of multiple tryptamine derivatives.
MindMed commences LSD microdosing study on various health-and-wellness benefits.
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
KCSA Communications hosts an investment conference featuring Rick Doblin (MAPS) as a keynote speaker.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now